Retatrutide: The Triple-Receptor Agonist

Compound deep-dive

Retatrutide explained: the triple-receptor agonist.

A 39-amino-acid synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. The first trinity agonist to publish a full Phase 2 dataset. The 12 mg arm of the obesity trial reported a 24.2 percent reduction in body weight at 48 weeks, the largest published figure for any single agent in this category to date. Phase 3 (TRIUMPH) is in progress.

By Marcus, founder· Published 6 May 2026· ~10 min read

TL;DR. Retatrutide (Eli Lilly codename LY3437943) is a 39-amino-acid synthetic peptide that simultaneously agonises three receptors: GIP, GLP-1, and the glucagon receptor. The trinity-agonist concept extends the dual-agonist tirzepatide architecture by adding the energy-expenditure arm produced through glucagon receptor activation, while the GLP-1 component continues to regulate glycaemia. Phase 2 data published in the New England Journal of Medicine (June 2023) reported a 24.2% body-weight reduction at the 12 mg weekly dose over 48 weeks, representing one of the largest reductions reported for a single investigational agent in this class. The Phase 3 TRIUMPH programme remains ongoing, and Retatrutide is not currently licensed as a medicine in any jurisdiction. Pure Peptides Lab supplies Retatrutide strictly as a research-grade reference peptide for laboratory and in-vitro research purposes only. Researchers should verify every batch by confirming: ✔ Single-peak HPLC chromatogram (99%+ purity), ✔ Mass spectrometry confirming approximately 4731 g/mol, and ✔ A uniform porous white lyophilised cake.

Research Quality Reminder

A Certificate of Analysis (COA) should always include peptide identity, molecular weight, HPLC chromatogram, purity percentage, and mass spectrometry confirmation—not simply the product name.

What Retatrutide actually is

Retatrutide is the laboratory designation for Eli Lilly’s investigational triple-receptor agonist LY3437943. The molecule is a 39-amino-acid synthetic peptide engineered to bind and activate three different G-protein-coupled receptors at the same time: GIP, GLP-1, and the glucagon receptor. The architecture follows the same long-acting lipopeptide design language as tirzepatide (a chimeric backbone, non-natural amino acid substitutions for protease resistance, a fatty acid modification on a lysine side chain to drive albumin binding) but the receptor-recognition surfaces are tuned to add glucagon-receptor agonism on top of the GIP and GLP-1 dual coverage that tirzepatide provides.

The key engineering decisions behind retatrutide were published in early discovery papers from the Lilly group and a series of subsequent characterisation studies. The molecule was designed so that all three receptor activities are present at meaningful but balanced potencies: too much glucagon-receptor activation would raise hepatic glucose output and undo the glycaemic benefit, whereas too little would lose the energy-expenditure arm that motivates including glucagon in the first place. The published Phase 2 data is the practical demonstration that the balance was achieved.

Codename	`LY3437943` (Eli Lilly)
Length	39 amino acids
Average MW	~4731 g/mol
Receptor profile	Triple agonist: GIP + GLP-1 + glucagon receptors
Lipid modification	C20 fatty diacid attached via gamma-Glu plus 2 x AEEA spacer (same architecture as tirzepatide)
Half-life	~6 days (~144 hours), enables once-weekly subcutaneous administration in published research literature
Albumin binding	High, mediated by the C20 fatty acid
Lyophilised stability	24+ months at 2–8 °C, sealed and protected from light
Regulatory status (2026)	Phase 3 (TRIUMPH series). Not yet licensed in any jurisdiction.

Why a third receptor arm

The trinity-agonist idea, in one paragraph.

GLP-1 alone gives you appetite suppression and a glucose-dependent insulin response. Adding GIP (the dual-agonist tirzepatide step) meaningfully amplifies the satiety and adipose-tissue effects beyond what GLP-1-only molecules achieve, despite earlier scepticism that GIP signalling was non-functional in type-2 diabetes. The third arm, glucagon-receptor agonism, brings something neither incretin axis directly provides: a measurable increase in basal metabolic rate, hepatic fat oxidation, and lipolysis from adipose stores.

The historical objection was that activating the glucagon receptor would raise hepatic glucose output and worsen glycaemic control. The retatrutide design counters this with the simultaneous GLP-1 component, whose insulinotropic and glucose-suppressive actions offset the glucagon-driven hepatic output. The published Phase 2 data is the practical evidence that the balance holds: HbA1c reductions of approximately 2 percentage points at the higher doses with body-weight reductions exceeding 24 percent at 48 weeks. Energy expenditure goes up, glycaemic control stays good, weight comes off.

The Phase 2 NEJM data

Two Phase 2 papers landed simultaneously in the New England Journal of Medicine on the same day in June 2023. They are the foundation document for retatrutide’s clinical profile.

Obesity trial (Jastreboff et al., NEJM 2023)

The headline obesity paper, Jastreboff et al. NEJM 2023, PMID 37356779, ran 338 adults with obesity (mean BMI 37.3) but without type-2 diabetes for 48 weeks against placebo. The numbers that propagated through every metabolic-research conversation:

Arm (weekly dose)	Mean body-weight change at 48 weeks	Loss ≥15% of body weight
Placebo	−2.1 %	~2%
Retatrutide 1 mg	−8.7 %	~17%
Retatrutide 4 mg	−17.1 %	~60%
Retatrutide 8 mg	−22.8 %	~75%
Retatrutide 12 mg	−24.2 %	~83%

For context, the equivalent SURMOUNT-1 figure for tirzepatide 15 mg over a longer 72-week period was a 20.9 percent body-weight reduction. Retatrutide hit a larger figure in a shorter trial. The slope of the weight-loss curve had not plateaued at the 48-week endpoint, suggesting further reductions over a longer treatment window.

Type 2 diabetes trial (Rosenstock et al., 2023)

The companion paper, Rosenstock et al., 2023, ran 281 adults with type 2 diabetes for 36 weeks. HbA1c reductions were approximately 2 percentage points at the higher doses, comparable to or larger than the figures published earlier for tirzepatide in the SURPASS programme.

The TRIUMPH Phase 3 programme

Phase 3 (TRIUMPH) is the definitive trial set. Four arms:

TRIUMPH-1 – chronic weight management in adults with obesity
TRIUMPH-2 – chronic weight management in adults with type 2 diabetes plus obesity
TRIUMPH-3 – chronic weight management in adults with cardiovascular disease and obesity
TRIUMPH-4 – knee osteoarthritis in adults with obesity

As of the date of this article retatrutide is not yet licensed as a medicine in any jurisdiction. The TRIUMPH outcomes are the trial set on which any future regulatory authorisation will rest.

The chemistry behind the once-weekly half-life

The lipid-modification strategy is the same one used for tirzepatide and semaglutide: a long-chain fatty diacid attached to a lysine side chain via a small linker, producing a molecule that binds reversibly to serum albumin and clears far more slowly than an unmodified peptide would. For retatrutide the modification is a C20 fatty diacid with a gamma-glutamic-acid plus 2 x AEEA spacer. The result is an effective half-life of around 6 days, which supports once-weekly subcutaneous administration in the published research dose-finding work.

For the bench scientist the practical consequence is that retatrutide reconstitutes cleanly into a clear colourless solution and behaves as a long-half-life lipopeptide in any in-vitro model that involves serum albumin. Like tirzepatide it is not unusually fragile but the standard cold-chain handling (amber glass, 2 to 8 degrees Celsius, no shaking, no freeze-thaw) is the right default.

What to look for on the Certificate of Analysis

If you’ve read our walk-through of a Janoshik HPLC report, the standard structure applies. For retatrutide specifically:

1. A single tall peak on the reversed-phase HPLC chromatogram

One dominant peak at the retatrutide retention time, a flat baseline elsewhere, and 99%+ purity in the analytical summary. Retatrutide is a difficult molecule to synthesise correctly and the synthesis route is not yet as commodified as tirzepatide; the chromatogram trace itself matters at least as much as the headline percentage.

2. Mass spectrometry confirmation of the ~4731 g/mol mass

Like tirzepatide, retatrutide is large enough that electrospray mass spectra show multiply-charged species rather than a single intact molecular ion. A real spectrum from Janoshik or any competent peptide-analysis lab will show a characteristic ladder of charge states (typically the [M+3H]3+, [M+4H]4+, [M+5H]5+ and [M+6H]6+ species at characteristic m/z values around 1578, 1184, 947 and 789) that cross-sum back to the average molecular mass.

3. The Janoshik verification key resolves on their portal

Every Janoshik certificate carries a short alphanumeric verification key. That key plus the task ID printed on the certificate can be cross-referenced on the issuing lab’s public records. A real retatrutide batch resolves; a fabricated COA does not.

Storage and handling at your bench

Refrigerate at 2–8 °C in the original sealed amber-glass vial. Retatrutide is stable for 24 months or more in the lyophilised state when kept dry, sealed, and protected from light.
Reconstitute with bacteriostatic water by adding the water slowly down the inside wall of the vial and gently swirling (not shaking, never vortexing) until the cake fully dissolves. The resulting solution should be clear and colourless. Cloudiness suggests undissolved peptide or contamination.
Reconstituted shelf life is shorter than the lyophilised form. The published preclinical analytical literature commonly references a window of four to six weeks under refrigeration; consult the specific assay or research method you are running for the exact figure.
Avoid freeze-thaw cycles on the reconstituted solution. The lipid modification makes retatrutide micelle-prone in solution and repeated freeze-thaw is the most common cause of activity loss.
Ship and store in amber glass. Retatrutide is less photolabile than copper-coordinated peptides like GHK-Cu, but cold-chain amber-glass shipping is the right default for any modern lipopeptide.

Common red flags when sourcing retatrutide

Walk-away signals when buying retatrutide

The lyophilised cake in the supplier’s product photos is yellowed, cream-coloured, or shown as a heap of loose granular powder rather than a uniform porous white cake. Retatrutide done correctly produces a clean white puck.
No batch-specific Certificate of Analysis included with the order. The chromatogram trace and the multiply-charged mass-spectrometry ladder both matter; “we test our products” on a website is not the same as a per-batch COA tied to the vial in your hand.
The COA carries no verification key, or the key does not resolve on the issuing lab’s public portal. Cross-check it yourself.
A chromatogram with multiple peaks of comparable height. Retatrutide synthesis is non-trivial; a chromatogram with a single dominant peak plus minor impurities is the correct shape, but several near-equal peaks usually means a mixed synthesis product or contamination with related peptides.
Mass-spectrometry data is absent, or shows only one of the multiply-charged species in isolation. A real retatrutide spectrum has a characteristic multi-charge-state ladder.
The supplier markets “retatrutide” capsules, sublingual sprays, or topical creams. These formats are inconsistent with the published research, are outside the research-reagent supply category we operate in, and are a near-universal indicator of a non-reputable seller.
A supplier claiming retatrutide is “approved”, “FDA-cleared”, “MHRA-cleared”, or available as a generic of any branded product. As of 2026 retatrutide is still in Phase 3 development under the TRIUMPH programme; any claim of regulatory authorisation is false.
Pricing far below the broader market rate. Retatrutide is a difficult molecule to synthesise to 99%+ purity and a vial advertised at a fraction of the going rate is often a vial of an older, easier-to-synthesise GLP-1 or GIP/GLP-1 analogue with a retatrutide label on it.
Vial label has no batch number, no fill weight, or no manufacturer identifier.

Where this fits in the metabolic-research family

Retatrutide is the third generation of the long-acting incretin-family architecture, building on the first generation (GLP-1-only compounds like semaglutide) and the second generation (dual GIP/GLP-1 like tirzepatide). Our side-by-side write-ups cover the trade-offs between the three generations:

Tirzepatide vs Retatrutide – dual vs triple receptor agonism
Semaglutide vs Retatrutide – single-target vs trinity agonist
Tirzepatide vs Semaglutide – dual vs single agonist for context

What we supply

We stock retatrutide as a lyophilised cake in 10mg, 20mg, 30mg and 40mg amber-glass vials, plus a pre-filled pen format in matching dose strengths, independently HPLC-verified by Janoshik Analytical to 99%+ purity. The Janoshik Certificate of Analysis ships in the box with every order where one is available for the current batch, and the report is also published on our Purity page for independent reference. The product page with current pricing, the integrated dose calculator (built around the Phase 2 dose-titration ladder of 2 / 4 / 8 / 12 mg weekly used in Jastreboff 2023), and the BAC-water option is at /peptides/retatrutide.html.

Important regulatory note. Retatrutide is in active Phase 3 clinical development under Eli Lilly’s TRIUMPH programme. As of 2026 it is not licensed as a medicine by the FDA, MHRA, EMA, or any other major regulator, and there is no branded prescription product equivalent. Pure Peptides Lab Ltd supplies retatrutide as a research-grade reference reagent for laboratory and in-vitro research only, with no human or veterinary use intended or implied. The published Phase 2 data is preliminary; the TRIUMPH outcomes will define the definitive efficacy and safety picture. We do not provide therapeutic claims, dosing guidance, or administration protocols.

Research use only. The compound information described above is drawn from peer-reviewed analytical and clinical literature and is provided for laboratory and in-vitro research context.